Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Scholarly Papers
1-1-2021

Evaluation of albumin use in a community hospital setting: A
retrospective study looking at appropriate use and prescribing
patterns.
Timothy Coyle
Samuel John
Philadelphia College of Osteopathic Medicine, samueljo@pcom.edu

Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Coyle, Timothy and John, Samuel, "Evaluation of albumin use in a community hospital setting: A
retrospective study looking at appropriate use and prescribing patterns." (2021). PCOM Scholarly Papers.
2134.
https://digitalcommons.pcom.edu/scholarly_papers/2134

This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for
inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more
information, please contact jaclynwe@pcom.edu.

PLOS ONE
RESEARCH ARTICLE

Evaluation of albumin use in a community
hospital setting: A retrospective study looking
at appropriate use and prescribing patterns
Timothy Coyle1, Samuel M. John ID2*
1 PGY-2 Medication Use Safety and Policy, Wellstar Health System, Marietta, GA, United States of America,
2 Department of Pharmacy Practice, PGY-1 Residency Program, PCOM Georgia, Suwanee, GA, United
States of America

a1111111111
a1111111111
a1111111111
a1111111111
a1111111111

* SamuelJo@pcom.edu

Abstract
Purpose

OPEN ACCESS
Citation: Coyle T, John SM (2021) Evaluation of
albumin use in a community hospital setting: A
retrospective study looking at appropriate use and
prescribing patterns. PLoS ONE 16(10): e0257858.
https://doi.org/10.1371/journal.pone.0257858
Editor: Aleksandar R. Zivkovic, Heidelberg
University Hospital, GERMANY
Received: June 17, 2021
Accepted: September 11, 2021
Published: October 6, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0257858
Copyright: © 2021 Coyle, John. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its supporting information
files.
Funding: The authors received no specific funding
for this work.

Albumin has been shown to be safe and effective in clinical practice for a wide variety of indications. The purpose of this medication use evaluation is to quantify the use of albumin in
the community hospital setting based on indication and prescribing department.

Methods
This study is a retrospective, single-center, chart review over a 6-month period of 186
patients aged 18 and older who were treated with IV human albumin 5% or 25% at a single
202-bed community hospital setting from February 1, 2020, to August 1, 2020. A chart
review was completed for each patient and the data collected included date of albumin
administration, the ordering provider, the specialty of the provider, the indication for albumin
as stated in the order, patient notes, crystalloid therapy use prior to albumin, albumin
strength, the presence of acute or chronic renal, hepatic or respiratory disorders, and lab
values denoting renal and hepatic function. Appropriate albumin use was determined utilizing criteria which included FDA labeled indications, the Surviving Sepsis Campaign, and
existing literature.

Results
A total of 186 patients received albumin 5% or 25% IV solution at least once during the study
period. The study population was 52.2% female, and the average age was 68 years. Of the
patients selected for the study, 23 (11.6%) had chronic hepatic disease, and 37 (18.7%) had
chronic renal disease. The top indications for which albumin was administered were sepsis
or septic shock (25.3%), hypotension or hypovolemia (19.4%), intra-dialytic hypotension
(13.4%), fluid support in surgery (10.8%), and nephrosis or nephropathy (10.8%). The
departments with highest albumin use during this study period were critical care (41%),
nephrology (28%), and surgery (17%). Overall, albumin was used for an appropriate indication in 126 out of 186 patients (67.7%).
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Conclusion
We found that albumin was most utilized for sepsis and septic shock, hypovolemia and
hypotension, and intradialytic hypotension in our community hospital setting and it was most
frequently ordered by critical care, nephrology, and surgical departments. Further research
could determine if this trend is seen in other community hospital settings.

Introduction
Albumin has been used clinically for multiple indications, including fluid resuscitation and
support in pulmonary, renal and hepatic conditions [1,2]. It is associated with higher cost of
therapy compared to crystalloids, making its use somewhat controversial there is no comparable benefit of using albumin over crystalloids [3]. The Saline versus Albumin Fluid Evaluation
(SAFE) trail in 2004 showed that 4% albumin was comparable to normal saline when used for
resuscitation [2,3]. In recent years, more guidelines for albumin use have been utilized in multiple healthcare systems, even though clinical benefit of using albumin is unclear [4,5].
The current FDA-labeled indications for albumin are acute respiratory distress syndrome,
cirrhotic ascites, erythrocyte resuspension, hypovolemia, neonatal hemolytic disease, and
adjunct treatment for nephrosis in combination with diuretics.1 Albumin is also included in
the Surviving Sepsis campaign for patients that are hypovolemic that require large volumes of
crystalloids [6,7]. There are multiple off-label uses of albumin within an acute care setting, and
variability of albumin use remains high between providers, regardless of the presence of guidelines for appropriate use [8].
Multiple studies have shown the cost-reduction potential of restricting albumin use, but
these were focused on the critical care setting, and there is less data for the overall albumin use
within a community hospital setting [7,9]. The purpose of this medication use evaluation is to
quantify the use of albumin in a community hospital setting. The results could be used to
describe the use of albumin by department and to provide information regarding the departments that utilize albumin the most in the current healthcare setting.

Objectives
The primary objective was to determine the prescribing practices of albumin use by indication
for a community hospital setting. The secondary objective was to determine appropriate use of
albumin based on existing literature, including the FDA labeled indications, indications from
the Surviving Sepsis Campaign and from the study conducted by Buckley et al regarding pharmacist intervention in albumin use [1,6,9].

Materials and methods
This is a retrospective, single-center, chart review over a 6-month period from February 1,
2020, to August 1, 2020 of 186 patients who were treated with IV human albumin 5% or 25%
at a community hospital (Wellstar North Fulton Hospital) consisting of 202 patient beds, 27 of
which are adult ICU beds. At the time of this study, the hospital services included a level-2
trauma center, adult ICU, and medical and surgical floors. This study was evaluated by the
Wellstar Research Institute and determined to be waived from the institutional review board.
After collection of data from the patients’ charts, the patients’ information was anonymized
prior to evaluation of the data. Patients were included if they were aged 18 or older and
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received at least one dose of albumin during their time in the hospital. Patients were excluded
if they did not receive a dose of albumin during their hospital stay. Descriptive analysis including frequencies and percentages of all requested variables was performed, using mean and
standard deviation, as appropriate. This was a descriptive chart review, and no statistical tests
were employed.
A medication report was generated in the electronic medical record software, Epic1, for
patients within the hospital who received IV albumin during their admission between the
dates February 1, 2020, to August 1, 2020. A chart review of the patients was then conducted in
which the indication for albumin use was determined from the order that was entered, from
the note from the provider or a note on which the ordering provider was the co-signer, and
through the medication profile review. The data collected included patient demographics
including age, gender ethnicity, and chronic hepatic or renal disease, if any. Additional data
included the date albumin was first administered, the ordering provider, the specialty of the
ordering provider, the indication or interpreted indication of albumin, crystalloid therapy
prior to the use of albumin, albumin strength, the presence of acute or chronic renal, hepatic,
or respiratory disease, as included in the previous medical history of the patient chart, and
renal and hepatic lab values (SCr, BUN, eGFR, AST, ALT, serum albumin, total bilirubin).
Appropriate indications of albumin were determined utilizing a criteria that was made
using the FDA-approved indications, the Surviving Sepsis Campaign, and the indications considered appropriate by Buckley, et al [1,6,9]. The uses of albumin that were considered appropriate included acute respiratory distress syndrome, cirrhotic ascites, hypovolemia, nephrosis
or nephropathy, fluid resuscitation in septic shock in combination with crystalloid therapy,
cardiovascular surgery, large volume paracentesis greater than five liters, hepatorenal syndrome, and therapeutic plasma exchange [1,6,9]. For indications that were outside of these criteria, the use was considered inappropriate.

Results
A total of 194 patients were screened. Of these patients, 186 received albumin 5% or 25% IV solution at least once during the study period. Table 1 describes baseline characteristics of the patient
population. The study population was 52.2% female and had an average age of 68 years. Onehundred and twenty-two patients (65.6%) identified as white or Caucasian, 30 patients (16.1%)
Table 1. Baseline characteristics.
Baseline Characteristics (n = 186)
Male, n (%)

89 (47.8%)

Female, n (%)

97 (52.2%)

Average Age, years ± SD

68 ± 15

Ethnicity, n (%)
White/Caucasian

122 (65.6%)

African American

30 (16.1%)

Hispanic or Latino

15 (8.1%)

Asian

5 (2.7%)

Other

14 (7.5%)

Chronic Hepatic Disease, n (%)

23 (11.6%)

Chronic Renal Disease, n (%)

37 (18.7%)

Albumin Product Used, n (%)
5%

46 (24.7%)

25%

140 (75.2%)

https://doi.org/10.1371/journal.pone.0257858.t001
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identified as African American, and 15 patients (8.1%) identified as Hispanic or Latino. Of the
patients selected for the study, 23 (11.6%) had chronic hepatic disease, and 37 (18.7%) had
underlying chronic renal disease. Most of the patients (75.2%) received albumin 25% solution.
The indications for albumin use with the largest number of patients over the 6-month study
period were sepsis or septic shock (25.3%), hypotension or hypovolemia (19.4%), intra-dialytic
hypotension (13.4%), fluid support in surgery (10.8%), and nephrosis or nephropathy (10.8%)
(Table 2). Other indications representing less than 5% of the albumin use included acute respiratory distress syndrome (ARDS), paracentesis, hyponatremia, hypervolemia or edema, cirrhosis, hepatorenal syndrome, respiratory failure, and hypoalbuminemia in liver disease.
Overall, 126 out of 186 patients (67.7%) in this study were administered albumin for an
appropriate indication as defined by our criteria utilizing the FDA-labeled indications, Surviving Sepsis Campaign guidelines, and the study by Buckley and colleagues [9]. Albumin was
used appropriately in the 47 patients presenting with sepsis or septic shock, the 36 patients presenting with hypotension or hypovolemia, and the 20 patients presenting with nephrosis or
nephropathy. Albumin was considered inappropriate in the setting of dialysis and fluid support in surgery. Four of the 7 patients with paracentesis were administered albumin appropriately, and three were not due to volume of paracentesis being below 5 liters. Other appropriate
indications as defined by the criteria included cirrhosis, hepatorenal syndrome, hypoalbuminemia in liver disease, hepatic hydrothorax, plasmapheresis, and therapeutic plasma exchange.
Other inappropriate indications for which albumin was used were hyponatremia, hypervolemia, and respiratory failure (Fig 1).
Most of the orders for albumin were prescribed by providers specializing in critical care,
nephrology, or surgery. Fig 2 shows the prescribing patterns of physicians in the community
hospital setting based on specialty of the prescriber. Of the patients that received albumin in
this study, 41% were given albumin as ordered by critical care, 28% of patients were administered albumin from nephrology orders, and 17% were administered albumin from surgical
orders. Other departments that prescribed and administered albumin in this study period
Table 2. Albumin use by indication.
Indication

Number of Patients Who Received One or More Doses of Albumin, n (%)

Sepsis/Septic Shock

47 (25.3%)

Hypovolemia/Hypotension

36 (19.4%)

Intra-dialytic Hypotension

25 (13.4%)

Fluid Support in Surgery

20 (10.8%)

Nephrosis/Nephropathy

20 (10.8%)

Paracentesis

7 (3.8%)

ARDS

7 (3.8%)

Hyponatremia

6 (3.2%)

Hypervolemia

4 (2.2%)

Cirrhosis

3 (1.6%)

Hepatorenal Syndrome

3 (1.6%)

Respiratory Failure

2 (1.1%)

Hypoalbuminemia in Liver Disease

2 (1.1%)

Hepatic Hydrothorax

1 (0.5%)

Plasmapheresis

1 (0.5%)

Thoracentesis

1 (0.5%)

Therapeutic Plasma Exchange

1 (0.5%)

Total

186

https://doi.org/10.1371/journal.pone.0257858.t002
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Fig 1. Albumin use by initial indication (February 1, 2020–August 1, 2020). AKI indicates acute kidney injury,
ARDS indicates acute respiratory distress syndrome.
https://doi.org/10.1371/journal.pone.0257858.g001

include hospital medicine, gastroenterology, cardiology, respiratory medicine, emergency
medicine, and gynecology/oncology.

Discussion
Our study showed that albumin was used for an appropriate indication in 126 out of 186
patients (67.7%). The criteria for appropriate use were created by utilizing FDA approved indications, the Surviving Sepsis Campaign and the previously completed study completed by
Buckley et al [1,6,9]. The criteria for appropriate use were intentionally made to be broad to
account for provider experience and variability. We used the study completed by Buckley,
et al, to build our criteria due to the pharmacist-led strategy that their method employed [9].
This would also help to see if criteria for appropriate use of albumin is applicable between
practice sites [9].
Albumin is considered appropriate when used in the context of sepsis and septic shock
after crystalloid therapy is given first. The evidence for albumin benefit in sepsis or septic
shock is unclear [10,11]. The study completed by Caironi et al and showed that there was no
difference in mortality for patients with septic shock between patients receiving albumin versus normal saline, but a meta-analysis by Xu et al showed a trend toward lower 90-day mortality in severe sepsis patients treated with albumin versus crystalloid therapy [10,11]. This
suggests further studies still need to be performed to establish any significant benefit of albumin over crystalloid therapy [10,11].

Fig 2. Albumin administrations as prescribed by specialty. Other: Gastroenterology, physical medicine, cardiology,
respiratory, emergency medicine, gynecology oncology.
https://doi.org/10.1371/journal.pone.0257858.g002
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In our study, we saw more albumin use in the context of nephrology. Second to critical
care, it was the highest practice that wrote orders for albumin. While it can be used in patients
with hepatorenal syndrome to increase renal function, it can also be used in patients with
nephrosis or nephrotic syndrome may warrant future studies [12]. In one study, furosemide
with albumin produced favorable results, increasing the pharmacologic effects of furosemide,
though further studies should be performed [13].
The area in which albumin use was considered inappropriate in this study was fluid support
in the setting of non-cardiovascular surgery. The surgical procedures that utilized albumin
included genitourinary, hip, ovarian, neurologic, or trauma surgeries. According to the current literature, the preferred solutions for fluid resuscitation in these types of surgeries are
crystalloids [9,10]. It should be noted, however, that the hospital procedure for this site permit
albumin to be used in the surgical setting if crystalloid therapy is utilized first. Further studies
could analyze albumin use in the surgical setting.
Albumin use was also considered inappropriate in the setting of intradialytic hypotension
[1,9]. Although off-label use exists for fluid support during dialysis, the criteria utilized in this
study did not include dialysis as an appropriate indication. The hospital order set, however, allows
for albumin to be utilized for patients receiving hemodialysis if they were hypotensive despite
crystalloid therapy alone, which may be a reason that use was high in the setting of hemodialysis.
The albumin use in this study is comparable to other studies of albumin use within a hospital setting. The study by Castillo, et al found that approximately 45% of albumin was prescribed
inappropriately according to their guidelines [14]. Similarly, the study conducted by Buckley
et al showed that up to 63.4% of albumin administered was considered inappropriate, although
their criteria was more stringent [9].
There is potential for pharmacist intervention in reducing inappropriate albumin use.
Tigabu, et al, performed a cost analysis of albumin in septic shock that found that albumin use
increased the cost of medication therapy without improving the 28-day mortality compared to
normal saline [15]. Additionally, Buckley, et al, found that their pharmacist-led strategy led to
a 50.9% decrease of inappropriate use of albumin [9]. Future studies could include the goal of
developing criteria for appropriate albumin use within the hospital system.
One of the limitations of this study was the retrospective nature and reliance on chart
review as the primary data collection method. Another limitation is the wide variety of indications albumin, leading to some ambiguity in determining the indication for albumin, though
every effort was made to review the clinical notes, orders, and medication profile to determine
the most likely indication.

Conclusion
We found that albumin was most utilized for sepsis and septic shock, hypovolemia and hypotension, and intradialytic hypotension in our community hospital setting and it was ordered
by critical care, nephrology, and surgery departments. This study represents a single community hospital site, and further research could be conducted to determine if these trends are
seen in other community hospital settings.
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